Navigation Links
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
Date:2/27/2009

CRANBURY, N.J., Feb. 27 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that the Company has suspended enrollment for the Phase 2 clinical trial of its investigational drug AT2220 (1-deoxynojirimycin HCI) for the treatment of Pompe Disease and that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that the trial is on clinical hold. After evaluation of available data the Company plans to work closely with the FDA and if appropriate will amend the Phase 2 protocol with the objective of restarting the trial as expeditiously as possible.

Amicus initiated the Phase 2 clinical trial of AT2220 in adults with Pompe disease in June, 2008. Based on encouraging safety data from both preclinical and Phase 1 studies, the approved Phase 2 trial protocol involved initial treatment with a high dose of AT2220. Two patients enrolled in the trial experienced self-reported adverse events and subsequently withdrew from the trial. The events were categorized by the site investigator as serious and probably related to treatment with AT2220.

After initial evaluation of the events, Amicus suspended patient enrollment for the Phase 2 trial. In compliance with regulatory requirements and internal standard operating procedures, the two events were reported to the relevant health authorities, including FDA, and in a subsequent discussion with the FDA the trial was placed on clinical hold status pending further evaluation of the events.

John F. Crowley, President and CEO of Amicus commented, "We will work closely with the investigators and the FDA to address these issues, modify the protocol as appropriate, and get the trial back on track as quickly as possible. We are committed to exploring this new therapy for people living with Pompe disease in as safe a manner as possible."
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... ANGELES , Oct. 30, 2014 Migranade, ... Relief will be available to the 36 million U.S. ... a platform technology that targets the actual cause of ... medications attack pain and not the source Migranade is ... medication category. MIGRANADE Migraine Relief is available at ...
(Date:10/31/2014)... Oct. 31, 2014 Though therapies are in ... expected to show an annual increase of 16.2% over ... nearly $1 billion, according to Kalorama Information,s report, ... stem cell therapeutics that have gained or are expected ... "As drug developers tackle ever more complicated conditions, stem ...
(Date:10/30/2014)... 30, 2014 Stryker Orthopaedics, the Official Joint ... is rounding out its debut year of the relationship ... Scottsdale, AZ. This marks the eleventh tournament ... that the brand has activated on-site with the "Stryker ... fans on the importance of joint health.  ...
Breaking Medicine Technology:Game Changing Migraine Medication To Be Available November 2014 2Report: Stem Cell Technologies Market Growing 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4
... 2011 eCardio Diagnostics ( www.ecardio.com ) announces three executive ... of its clients and the patients they serve. ... year has provided us with an opportunity to expand the ... Larry Lawson, President & Chief Executive Officer. Robert ...
... Reportlinker.com announces that a new market ... Medical Devices Reports Bundle ... The Medical Devices Reports Bundle includes ... discount off the individual reports being purchased separately: ...
Cached Medicine Technology:Reportlinker Adds Medical Devices Reports Bundle 2Reportlinker Adds Medical Devices Reports Bundle 3Reportlinker Adds Medical Devices Reports Bundle 4Reportlinker Adds Medical Devices Reports Bundle 5Reportlinker Adds Medical Devices Reports Bundle 6Reportlinker Adds Medical Devices Reports Bundle 7Reportlinker Adds Medical Devices Reports Bundle 8Reportlinker Adds Medical Devices Reports Bundle 9
(Date:10/31/2014)... and cost, patients with early stage breast cancer ... with proton therapy versus whole breast irradiation (WBI), ... Texas MD Anderson Proton Therapy Center. ... typical patient characteristics, researchers used Medicare reimbursement codes ... of partial and whole breast irradiation therapies and ...
(Date:10/31/2014)... Nearly one out of four older Americans say that ... or unwanted medical treatment, according to the latest issue ... & Aging Report ( PP&AR ), which goes ... accountable when they fail to honor patients, end-of-life health ... Advanced Illness Care: Issues and Options ," features 12 ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Gold Medal ... to find affordable but tasteful gifts for the wine novice ... Early Bird Gift Giving Special , which Early Bird ... they purchase Wine Club Gift membership. , Gift Givers ... of this special. Besides offering discounts, Gold Medal Wine Club ...
(Date:10/31/2014)... North Shore Eye Care today announced the ... and the addition of leading ophthalmologist, William S. Kasper, ... Shore Eye Care Medical Director, Jeffrey Martin, MD. , ... Department of Ophthalmology of Winthrop-University Hospital and has maintained ... more than 30 years. He has been named to ...
(Date:10/31/2014)... RESEARCH UK scientists have found a drug combination that ... - paving the way for new treatments, according to ... Research Institute (NCRI) Cancer Conference in Liverpool next week*. ... initiate a chain of events culminating in self destruction. ... and become immortal. This means that cells grow out ...
Breaking Medicine News(10 mins):Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Advance directives can benefit patients, families, and health care system 2Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... based venture-backed technology startup has been selected to ... (WEC25). The WEC25 Expo is an opportunity for ... a vast network of VCs and entrepreneurs. Delfigo ... identity and access management industry to offer a ...
... Wash., Feb. 4 drugstore.com , inc.,(Nasdaq: ... beauty, vision, and,pharmacy products, today announced its financial results ... 2008. The company reported,quarterly net sales of $93.9 ... fourth quarter gross margins of 28.5% and the highest ...
... Innovations, Inc.,(Nasdaq: YDNT ) today announced results for ... Sales for the fourth quarter of 2008 were ... $25.0 million reported in the fourth quarter,of 2007. Income ... of 2007 to $4.8 million in the fourth quarter of ...
... Andrew Cuomo and MVP Health Care today announced an ... not-for-profit organization to gather, maintain, and analyze provider reimbursement ... pay out of network providers using usual, customary and ... first involving an upstate New York based health insurer. ...
... 4 Pharmaceutical Research and Manufacturers of America ... following statement today regarding the State Children,s Health ... an expansion of the State Children,s Health Insurance ... of low-income, uninsured American families and, indeed, for ...
... might lead to better diagnosis and drug treatments, study ... who have the most common form of mental retardation ... a genetic mutation that may contribute to the condition, ... is that it occurs during development of the child ...
Cached Medicine News:Health News:Delfigo Security Selected as One of Twenty Five Most Promising Startups by The Wharton Entrepreneurship Conference 2Health News:Delfigo Security Selected as One of Twenty Five Most Promising Startups by The Wharton Entrepreneurship Conference 3Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 2Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 3Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 4Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 5Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 6Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 7Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 8Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 9Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 10Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 11Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 12Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 13Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 14Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 15Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 16Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 17Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 18Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 2Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 3Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 4Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 5Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 6Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 7Health News:MVP Health Care is First Upstate New York Based Health Insurer to Agree with Attorney General Andrew Cuomo on Out-Of-Network Provider Payment Reform 2Health News:PhRMA Statement on Expansion of SCHIP 2Health News:Gene Mutation Tied to Majority of Cases of Mental Retardation 2
22 mm. Plastic, methylmethacrylate, lightweight. Supplied sterile....
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
Size: Large. 24.50 mm by 26.00 mm. Clear lucite. Supplied sterile....
... Size: 2.3 x 6.4 x 80 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
Medicine Products: